Clinical trials: Diffuse Alveolar Hemorrhage
Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis
- Trial name
- NCT04098445
- Where
- 9 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati